The global COVID-19 vaccine surplus: tackling expiring stockpiles.

ABSTRACT:

Background

A global surplus of coronavirus disease 2019 (COVID-19) vaccines exists as a result of difficulties in aligning the demand and supply for vaccine manufacturing and delivery. World leaders have accelerated vaccine development, approval, production and distribution as a pragmatic approach to addressing the immediate public health challenges of the first two and a half years of the pandemic.

Main body

The currently predominant, highly transmissible Omicron variant of severe acute respiratory syndrome coronavirus 2 has brought us closer to the threshold required to achieve herd immunity by greatly increasing rates of natural infection. Paradoxically, in parallel with rising vaccination levels in industrialized nations, this indirectly reduces the need for mass vaccine

SUBMITTER: Quan NK 

PROVIDER: S-EPMC10025780 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature